FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington,	D.C. 20549
-------------	------------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL										
OMB Number:	3235-0287									
Estimated average burden										
hours per response:	0.5									

obligati Instruct	File	d pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940							934		hours	per re	sponse:	0.5			
Name and Address of Reporting Person*     Sensenig Bethany					2. Issuer Name and Ticker or Trading Symbol SUPERNUS PHARMACEUTICALS, INC. [SUPN]							C. Cr	eck all appli X Directo	•		10% O	
(Last) (First) (Middle) C/O SUPERNUS PHARMACEUTICALS, INC.					3. Date of Earliest Transaction (Month/Day/Year) 02/22/2024								Officer below)	(give title	itle Other (s below)		specify
9715 KEY WEST AVENUE					4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)						Lin	6. Individual or Joint/Group Filing (Check Applicable Line)				
(Street) ROCKVILLE MD 20850												X Form filed by One Reporting Person Form filed by More than One Reporting Person				I	
(City) (State) (Zip)  Rule 10b5-1(c) Transaction Indication  Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.									ed to								
			le I - No			_			quired, D	_						1	
1. Title of Security (Instr. 3)  2. Transa Date (Month/D					Execution D		Date	e, Transaction Disposed Code (Instr. 5)		rities Acquired (A) of d Of (D) (Instr. 3, 4		Benefici Owned F	rities For ficially (D) d Following (I) (		: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership	
						Code V	Amount	(A) o (D)	r Price	Reported Transact (Instr. 3	tion(s)			(Instr. 4)			
		T							uired, Dis s, options	•	,	,	Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Date,	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exerc Expiration D: (Month/Day/\)	ate	7. Title and Amount of Securities Underlying Derivative Securi (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Numbe derivative Securities Beneficia Owned Following Reported Transactie (Instr. 4)	e S Illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares					

## **Explanation of Responses:**

Director Stock Option (Right to Buy)

Restricted

Stock Units

1. The option vests on February 22, 2025.

\$27.94

(2)

- 2. Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting.
- 3. These restricted stock units will be settled in common stock upon vesting, which will occur on February 22, 2025.

/s/ Timothy C. Dec, as 02/26/2024 attorney-in-fact

\*\* Signature of Reporting Person Date

8,252

5,369

Stock

Common

Stock

\$0

\$<mark>0</mark>

8,252

5,369

D

D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

02/22/2024

02/22/2024

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

A

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

8,252

5,369

(1)

(3)

02/22/2034

(3)